Immutep reports ORR data for eftilagimod plus Keytruda in Phase I for melanoma

Immutep Ltd. (ASX:IMM; NASDAQ:IMMP) said eftilagimod alpha (IMP321) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to a best overall response rate (ORR) of 61% in 18 previously treated patients with unresectable or metastatic melanoma in the first three cohorts of the Phase I TACTI-mel trial. Additionally, 66% of patients were progression free six months after starting Keytruda.

The open-label, Australian TACTI-mel trial initially enrolled 18 patients that had a suboptimal response or disease progression with Keytruda monotherapy to receive six months of treatment with Keytruda once every three weeks plus 1, 6 or 30 mg subcutaneous eftilagimod every two weeks starting at the fifth Keytruda cycle...